Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
08 2023
Historique:
received: 31 03 2023
revised: 27 04 2023
accepted: 01 05 2023
medline: 21 7 2023
pubmed: 13 5 2023
entrez: 12 5 2023
Statut: ppublish

Résumé

Procoagulant platelets are a subpopulation of highly activated platelets that promote coagulation through surface-exposed, negatively charged phospholipids, especially phosphatidylserine. Procoagulant platelets are important for clot stabilization during hemostasis, and an increased number of these platelets is associated with thrombotic risk. There is a need for harmonization in this area since many of the markers and methods used to assess procoagulant platelets are not specific when used in isolation but are also associated with platelet apoptosis. We initiated this project to identify a minimum set of markers and/or methods that can detect and distinguish procoagulant platelets from apoptotic platelets. The study design involved a primary panel with 27 international experts who participated in an online survey and moderated virtual focus group meetings. Primary and secondary panel members were then invited to provide input on themes and statements generated from the focus groups. This led to a recommendation to use flow cytometry and a combination of the following 3 surface markers to differentiate procoagulant platelets from apoptotic platelets: P-selectin (CD62P), phosphatidylserine (recognized by annexin V), and the platelet-specific receptor GPIX (CD42a) or α Procoagulant platelets are expected to be positive for all 3 markers, while apoptotic platelets are positive for annexin V and the platelet-specific surface receptor(s) but negative for P-selectin.

Sections du résumé

BACKGROUND
Procoagulant platelets are a subpopulation of highly activated platelets that promote coagulation through surface-exposed, negatively charged phospholipids, especially phosphatidylserine. Procoagulant platelets are important for clot stabilization during hemostasis, and an increased number of these platelets is associated with thrombotic risk. There is a need for harmonization in this area since many of the markers and methods used to assess procoagulant platelets are not specific when used in isolation but are also associated with platelet apoptosis.
OBJECTIVES
We initiated this project to identify a minimum set of markers and/or methods that can detect and distinguish procoagulant platelets from apoptotic platelets.
METHODS
The study design involved a primary panel with 27 international experts who participated in an online survey and moderated virtual focus group meetings. Primary and secondary panel members were then invited to provide input on themes and statements generated from the focus groups.
RESULTS
This led to a recommendation to use flow cytometry and a combination of the following 3 surface markers to differentiate procoagulant platelets from apoptotic platelets: P-selectin (CD62P), phosphatidylserine (recognized by annexin V), and the platelet-specific receptor GPIX (CD42a) or α
CONCLUSION
Procoagulant platelets are expected to be positive for all 3 markers, while apoptotic platelets are positive for annexin V and the platelet-specific surface receptor(s) but negative for P-selectin.

Identifiants

pubmed: 37172731
pii: S1538-7836(23)00394-X
doi: 10.1016/j.jtha.2023.05.001
pii:
doi:

Substances chimiques

P-Selectin 0
Phosphatidylserines 0
Annexin A5 0
Platelet Glycoprotein GPIb-IX Complex 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2291-2299

Investigateurs

Ejaife O Agbani (EO)
Lorenzo Alberio (L)
Tamam Bakchoul (T)
Beth A Bouchard (BA)
Marina Camera (M)
Vivien Chen (V)
Fabrice Cognasse (F)
Judith M E M Cosemans (JMEM)
Rutvi G Dave (RG)
Frederik Denorme (F)
Dorothée Faille (D)
Alison H Goodall (AH)
Matthew T Harper (MT)
Johan Heemskerk (J)
Shawn M Jobe (SM)
Lacey Johnson (L)
Andaleb Kholmukhamedov (A)
Saptarshi Mandal (S)
Meganathan Kannan (M)
Diego Mezzano (D)
Nicola Mutch (N)
Margaret L Rand (ML)
Yana Roka-Moiia (Y)
Claudia Tersteeg (C)
Kimberly A Thomas (KA)
Dina Vara (D)
Yuping Yuan (Y)

Informations de copyright

Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interests J.H. is an adviser of Synapse Research Institute, Maastricht, The Netherlands. T.B. has a pending patent on using flow cytometry to detect procoagulant platelets in heparin induced thrombocytopenia. The work of L.A. and his research group on procoagulant collagen and thrombin platelets is currently supported by grants from Dr Henri Dubois-Ferrière Dinu Lipatti Foundation, Novartis Foundation for Medical-Biological Research (#18B074), the Swiss Heart Foundation (FF19117), and the Swiss National Science Foundation (320030-197392). The other authors report no conflicts of interest.

Auteurs

Emma C Josefsson (EC)

Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Laboratory Medicine, Institute of Biomedicine, The University of Gothenburg, Gothenburg, Sweden; Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia; Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.

Sofia Ramström (S)

Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Electronic address: sofia.ramstrom@oru.se.

Johannes Thaler (J)

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Marie Lordkipanidzé (M)

Faculté de pharmacie, Université de Montréal, Montréal, Québec, Canada; Research Center, Montreal Heart Institute, Montréal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH